Zoledronic acid (ZOL) significantly reduces skeletal-related events (SRES) versus clodronate (CLO) in patients (PTS) with multiple myeloma (MM): Results of the medical research council (MRC) Myeloma IX Study

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Author(s): Morgan G, Davies FE, Gregory WM, Bell SE, Szubert AJ, Coy NN, Drayson MT, Owen RG, Jackson GH, Child JA

Publication type: Conference Proceedings (inc. Abstract)

Publication status: Published

Conference Name: Annals of Oncology: 35th European Society for Medical Oncology (ESMO) Congress

Year of Conference: 2010

Pages: 350

ISSN: 0923-7534

Publisher: Oxford University Press

Library holdings: Search Newcastle University Library for this item

ISBN: 15698041

ePrints